Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumours

Interventions

DRUG: AZD4956
DRUG: Saruparib

Sponsor

AstraZeneca